Targeting the adipocytokine/PPAR signaling pathway affords an alternative therapeutic strategy to challenge the fibrofatty differentiation of IH, which can result in life-long, function-compromising effects including disfigurement. Here, PPARA is linked to isolated hemihyperplasia.